華禧聯合科技，歷時10年打造的新藥技術開發與管理團隊，持續提高企業創新能力與國際化程度，已從研發環境、儀器設備、人員配置、質量體系以及管理系統各層面對接國際標準。
華禧聯合科技，基于10年的新藥開發積累，與專業投資機構一起，通過并購重組，成功實現企業向產業化轉型。原料藥、口服固體制劑自主開發，生產線對接國際GMP認證，產品主要對接國外市場；鼻噴劑、滴眼劑等液體制劑主要承接國際技術轉移及加工合作，生產線對接國際GMP認證。
華禧聯合科技，期待通過與**企業的合作，向國際市場提供更具社會效益的高質量藥品，使華禧聯合科技成為一家倍受尊敬的國際制藥企業。
Huaxipharm has new drug technology and management teams with 10 years’ experience. Huaxipharm keep improving creating ability and degree of internationalization, and has complied with international standard on multiple levels, such as R&D environment, lab equipment, human resource allocation, file system and management system.
Huaxipharm, based on 10 years experience of new drug R&D,　achieve the industrialization of the enterprise transformation successfully by a new round of acquisition and reorganization. Huaxipharm’s API and Oral solid preparation are developed independently.　Production line of API and Oral solid preparation is facing international GMP certification and products are designed for foreign markets. For liquid preparation, such as nasal spray and eye drop, Huaxipharm is look for cooperation as technology transfer and OME. Production line of liquid preparation is facing international GMP certification.
Huaxipharm is looking forward to cooperate with outstanding enterprises, and provide high quality medicines of social benefits for international market, thus making Huaxipharm a respected international pharmaceutical company.